MAPS Responds to Report of Progress for MDMA-assisted therapy for PTSD with FDA

August 10, 2026 — The non-profit Multidisciplinary Association for Psychedelic Studies (MAPS) today responded to an August 9 report by Psychedelic Alpha indicating that Resilient Pharmaceuticals (formerly MAPS PBC and Lykos Therapeutics) has resubmitted its new drug application (NDA) for MDMA-assisted therapy for PTSD to the U.S. Food and Drug Administration (FDA). The resubmission follows… Continue reading MAPS Responds to Report of Progress for MDMA-assisted therapy for PTSD with FDA